Cabrera Laura Yenisa, Young Han Catherine, Ostendorf Tasha, Jimenez-Shahed Joohi, Sarva Harini
Center for Ethics and Humanities in the Life Sciences (LYC), Department of Translational Neuroscience, Michigan State University, East Lansing, current affiliation: Center for Neural Engineering, Department of Engineering Science and Mechanics, Rock Ethics Institutes, Pennsylvania State University; Weill Cornell Medicine (CYH), New York; American Academy of Neurology (TO), Minneapolis, MN; Bonnie and Tom Strauss Movement Disorders Center (JJ-S), Icahn School of Medicine at Mount Sinai, New York; and Parkinson's Disease and Movement Disorders Institute (HS), Department of Neurology, Weill Cornell Medicine, New York.
Neurol Clin Pract. 2021 Dec;11(6):506-516. doi: 10.1212/CPJ.0000000000001098.
We sought to explore current perspectives and attitudes of general neurologists and movement disorder specialists toward deep brain stimulation (DBS) for Parkinson disease (PD), focusing on perspectives on its earlier use in the clinical course of the disease.
We designed a 30-question online survey comprised of Likert-type, multiple choice, and rank-order questions, which was distributed to 932 neurologist members of the American Academy of Neurology. We analyzed clinicians' sociodemographic information, treatment patterns used for patients with PD, reasons for and against patient referral for DBS, and general attitudes toward DBS. Data were analyzed using descriptive and inferential statistics.
We received 164/930 completed surveys (completion rate of 18%). Overall, most respondents agreed that DBS was more useful after the appearance of motor complications and that DBS utilization offered better management of PD than medication alone. However, respondents were divided on issues like minimum duration of disease needed to consider DBS as a treatment option and timing of DBS referral relative to disease progression. Specifically, differences between movement disorder specialists and general neurologists were seen in medication management of symptoms and dyskinesia.
There remains a lack of consensus on several aspects of DBS, including medical management before offering DBS and the appropriate timing of its consideration for patients. Given the effect of such lack of consensus on patients' outcomes and recent evidence on positive DBS results, it is essential to update DBS professional guidelines with a focus on medical management and the timely use of DBS.
我们试图探究普通神经科医生和运动障碍专家对帕金森病(PD)深部脑刺激(DBS)的当前观点和态度,重点关注其在疾病临床过程中更早使用的观点。
我们设计了一项包含30个问题的在线调查,包括李克特式、多项选择和排序问题,该调查分发给了美国神经病学学会的932名神经科医生成员。我们分析了临床医生的社会人口统计学信息、用于PD患者的治疗模式、支持和反对将患者转诊接受DBS的原因以及对DBS的总体态度。使用描述性和推断性统计分析数据。
我们收到了164/930份完整的调查问卷(完成率为18%)。总体而言,大多数受访者同意DBS在运动并发症出现后更有用,并且DBS的应用比单独使用药物能更好地管理PD。然而,在将DBS视为一种治疗选择所需的最短病程以及相对于疾病进展的DBS转诊时机等问题上,受访者存在分歧。具体而言,在症状和异动症的药物管理方面,运动障碍专家和普通神经科医生之间存在差异。
在DBS的几个方面仍缺乏共识,包括在提供DBS之前的药物管理以及对患者考虑使用DBS的适当时间。鉴于这种缺乏共识对患者预后的影响以及最近关于DBS积极结果的证据,更新DBS专业指南以关注药物管理和DBS的及时使用至关重要。